Evidence map›Paper›PMID 24088786›Full record

ArticleMolecular cancer research : MCR2013

Systematic screen identifies miRNAs that target RAD51 and RAD51D to enhance chemosensitivity.

Jen-Wei Huang, Yemin Wang, Kiranjit K Dhillon, Philamer Calses, Emily Villegas, Patrick S Mitchell, Muneesh Tewari, Christopher J Kemp, Toshiyasu Taniguchi

Open access · bronzeAbstract read
In one paragraph

Article in Molecular cancer research : MCR, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 60 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
60citing papers in PubMed, 1 pooled it
3.8field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

60 citing papers in PubMed, 1 synthesis or guideline pooled it, 94 citations in OpenAlex.

  1. Pooled it
  2. Impact of germlineMolecular therapy. Oncology · 2026
    Article
  3. Article
  4. Review
  5. Review
  6. mRNA Expression and Methylation of theBiomarker insights · 2024
    Article
  7. Article
  8. Review
  9. Article
  10. Review
  11. Review
  12. Article
  13. Article
  14. Review
  15. Article
  16. Article
  17. Article
  18. Review
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 3 institutions in 1 country.

Jen-Wei HuangFred Hutchinson Cancer Research Center, 1100 Fairview Avenue North, C1-015, Seattle, WA 98109-1024. ttaniguc@fhcrc.org.
Yemin Wang
Kiranjit K Dhillon
Philamer Calses
Emily Villegas
Patrick S Mitchell
Muneesh Tewari
Christopher J Kemp
Toshiyasu Taniguchi
Howard Hughes Medical Institute · USUniversity of Washington · USFred Hutch Cancer Center · US

Funding

TRAINING IN MOLECULAR AND CELLULAR BIOLOGYT32GM007270 · NIGMS · UNIVERSITY OF WASHINGTON · PI RAIBLE, DAVID W · 1985 to 2020
$21.0M
Chromosome Metabolism and Cancer Training GrantT32CA009657 · NCI · FRED HUTCHINSON CANCER RESEARCH CENTER · PI EISENMAN, ROBERT NEIL · 1991 to 2020
$7.6M
The Fanconi Anemia-BRCA Pathway And Chemosensitivity of Human CancerR01CA125636 · NCI · FRED HUTCHINSON CANCER RESEARCH CENTER · PI TANIGUCHI, TOSHIYASU · 2007 to 2011
$1.6M
MicroRNAs Regulating The Fanconi Anemia-BRCA PathwayR21HL092978 · NHLBI · FRED HUTCHINSON CANCER RESEARCH CENTER · PI TANIGUCHI, TOSHIYASU · 2008 to 2009
$468k
Howard Hughes Medical InstituteNCI NIH HHS R01 CA125636NCI NIH HHS T32 CA009657NCI NIH HHS T32 CA 09657NHLBI NIH HHS R21 HL092978NIGMS NIH HHS 2T32 GM007270NIGMS NIH HHS T32 GM007270
6 · The paper itself

Abstract

unlabelledHomologous recombination mediates error-free repair of DNA double-strand breaks (DSB). RAD51 is an essential protein for catalyzing homologous recombination and its recruitment to DSBs is mediated by many factors including RAD51, its paralogs, and breast/ovarian cancer susceptibility gene products BRCA1/2. Deregulation of these factors leads to impaired DNA repair, genomic instability, and cellular sensitivity to chemotherapeutics such as cisplatin and PARP inhibitors. microRNAs (miRNA) are short, noncoding RNAs that posttranscriptionally regulate gene expression; however, the contribution of miRNAs in the regulation of homologous recombination is not well understood. To address this, a library of human miRNA mimics was systematically screened to pinpoint several miRNAs that significantly reduce RAD51 foci formation in response to ionizing radiation in human osteosarcoma cells. Subsequent study focused on two of the strongest candidates, miR-103 and miR-107, as they are frequently deregulated in cancer. Consistent with the inhibition of RAD51 foci formation, miR-103 and miR-107 reduced homology-directed repair and sensitized cells to various DNA-damaging agents, including cisplatin and a PARP inhibitor. Mechanistic analyses revealed that both miR-103 and miR-107 directly target and regulate RAD51 and RAD51D, which is critical for miR-103/107-mediated chemosensitization. Furthermore, endogenous regulation of RAD51D by miR-103/107 was observed in several tumor subtypes. Taken together, these data show that miR-103 and miR-107 overexpression promotes genomic instability and may be used therapeutically to chemosensitize tumors. IMPLICATIONS: These findings demonstrate a role for miR-103 and -107 in regulating DNA damage repair, thereby identifying new players in the progression of cancer and response to chemotherapy.

Indexed as

Recombinational DNA RepairCell Line, TumorCisplatinDNA-Binding ProteinsDNA Breaks, Double-StrandedGene Expression Regulation, NeoplasticGenomic InstabilityHeLa CellsHumansMicroRNAsOsteosarcomaPhthalazinesPiperazinesRad51 RecombinaseCisplatinDNA-Binding ProteinsMicroRNAsMIRN103 microRNA, humanMIRN107 microRNA, humanolaparibPhthalazinesPiperazinesRAD51D protein, humanRAD51 protein, humanRad51 Recombinase

Identifiers

PMID24088786
PMCPMC3869885
OpenAlexW2171039798

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.